The uremic dyslipoproteinemia: its characteristics and relations to clinical factors.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D001581:Benzothiadiazines; D002784:Cholesterol / Q000097:blood; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004232:Diuretics; D005215:Fasting; D005260:Female; D049711:History, Modern 1601-; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012737:Sex Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000319:Adrenergic beta-Antagonists; D000863:Antacids; D001581:Benzothiadiazines; D004040:Dietary Carbohydrates; D004232:Diuretics; D008074:Lipoproteins; D049993:Sodium Chloride Symporter Inhibitors; D014280:Triglycerides; D002784:Cholesterol